Results 231 to 240 of about 5,547 (244)

Phase III randomized study of the proposed adalimumab biosimilar GP2017 in psoriasis: impact of multiple switches

British Journal of Dermatology, 2018
Andrew Blauvelt
exaly  

To switch or not to switch: results of a nationwide guideline of mandatory switching from originator to biosimilar etanercept. One-year treatment outcomes in 2061 patients with inflammatory arthritis from the DANBIO registry

Annals of the Rheumatic Diseases, 2019
Bente Glintborg, Anne Gitte Loft, Oliver Hendricks   +2 more
exaly  

Efficacy and Safety of the Biosimilar Infliximab CT-P13 Treatment in Inflammatory Bowel Diseases: A Prospective, Multicentre, Nationwide Cohort

Journal of Crohn's and Colitis, 2016
Klaudia Farkas, Ferenc Nagy, Károly Palatka   +2 more
exaly  

Heterogeneity in learning processes and the evolution of dynamic managerial capabilities as a response of emergence of biosimilar market: evidence from the Indian pharmaceutical industry

, 2017
Dinar Kale, Farah Huzair
openalex   +1 more source

Long‐term efficacy and safety of biosimilar infliximab (CT‐P13) after switching from originator infliximab: open‐label extension of the NOR‐SWITCH trial

Journal of Internal Medicine, 2019
exaly  

Biosimilars: A revolution for biologics in the pharmaceutical industry

, 2017
Shannon Sherwin Moreino
openalex  

Physicochemical and Functional Comparability Between the Proposed Biosimilar Rituximab GP2013 and Originator Rituximab

BioDrugs, 2013
exaly  

Challenges of the recombinant pharmaceutical biosimilar proteins expression and enhanced refolded recovery from E. coli

, 2015
Vivek Kumar Morya
openalex  

The advantages and disadvantages of biosimilar pharmaceuticals

, 2016
Natalia Kakko
openalex  

New sources of growth under the TRIPS compliant patent regime for emerging country pharmaceutical industries?: Investigating the development of biosimilar capabilities in the Indian pharmaceutical sector

, 2015
Dinar Kale, Farah Huzair
openalex